GH
Gwenn Hansen (Chief Scientific Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Nurix Therapeutics, Inc. (NRIX). The largest single filing was $109K of NRIX (4,356 sh × $25.00, as filed), executed Aug 5. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$321K
shares × price, as filed
Last traded
Oct 30
Filed Nov 2
Median ADV $54.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $321K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
NRIXRecent filings
NRIXSALE
Nurix Therapeutics, Inc.
View filing →
$104K3,957 sh × $26.28
Exec Oct 30
Filed Nov 2 · 7:42 PM ET NRIXSALE Nurix Therapeutics, Inc. View filing → $109K
4,356 sh × $25.00
Exec Aug 5
Filed Aug 5 · 6:59 PM ET NRIXSALE Nurix Therapeutics, Inc. View filing → $108K
5,394 sh × $20.00
Exec Jun 25
Filed Jun 25 · 5:30 PM ET